News & Insights

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Functional, Sensorimotor, and Cognitive Outcomes Following Unilateral MCAO in Rats

Behavioral and pharmacological characterization of the isosorbide dinitrate model of headache in male and female rats

Filters

Filters

Therapeutic Areas

Specific Disorders

Filters

PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery

5 Women Leading the Way in Biotech

PsychoGenics Highlights a Long-term Collaboration with the TSC Alliance on Rare Disease Day

The Next Generation of Antidepressants and Antipsychotics

Immunotherapy Targeting the C-Terminal Domain of TDP-43 Decreases Neuropathology and Confers Neuroprotection in Mouse Models of ALS/FTD

2023 Pharma Predictions

PsychoGenics CEO Explores CNS Drug Development Trends

What Will the 2023 Drug Discovery Landscape Look Like?

Optimization and validation of profiling efforts within the NINDS preclinical screening platform for pain (PSPP) to accelerate the development of novel non-opioid, non-addictive pain therapeutics

Let’s Find the Right Solution Together

Quick Links

Contact

Address

Email

Phone

Fax